Gerson Lehrman Group - Intelligently Connecting Institutions and Expertise.

Kuldeepak Sharma, PhD

President/Pharmaceutical Consultant, Dr. Kuldeepak Sharma

What is a GLG Leader?|GLG Leaders are a separate tier of Council Members with a Council Rank in the top 5%. These GLG Member Program participants are eligible for ongoing, in-depth consultative relationships with GLG clients.

Member of the Healthcare Council

Council Member Biography

Kuldeepak Sharma, PhD, is a pharmaceutical consultant with twenty years of experience in research, clinical trials, business, patent and product development including: new process & technology development; clinical, project leadership; project planning; project management; patent research; managing research, design and engineering (R,D&E) groups. Dr. Sharma is organized, innovative and entrepreneurial. He is the inventor of ten US patents (four filed, six issued) and has authored about 12 journal papers and 3 book review chapters. Dr. Sharma has developed a unique drug / technology selection model for various drug delivery platforms. Dr. Sharma has successfully transferred the complex drug delivery technology from Japan to USA. A local company has used this model in technology selection and saved about 900K dollars with the help of this model. (This is me - Update Profile)


Employment History

2003 - present
President/Pharmaceutical Consultant, Dr. Kuldeepak Sharma

GLG NewsSM Analyses by Kuldeepak Sharma, PhD(?)

Opinions and analyses expressed in GLG News are solely those of the author. See the Terms of Use for details.

Good and Bad From Astellas Joint Venture With Maxygen

July 5, 2009

Kuldeepak Sharma, PhD, President/Pharmaceutical Consultant, Dr. Kuldeepak Sharma

Astellas Announces Joint Venture with Maxygen to Develop Protein Pharmaceuticals | www.pipelinereview.com

I read this news with great interest. This joint venture called (MPC) will advance Maxy 4 development program for rheumatoid arthritis and transplant rejection. Maxygen & Astellas  are committing $ 10 million each for this joint venture. Since I have worked with Astellas (Yamanouchi) and based...

Efalizumab Withdrawn Due to Serious Side Effect

April 16, 2009

Kuldeepak Sharma, PhD, President/Pharmaceutical Consultant, Dr. Kuldeepak Sharma

Efalizumab withdrawn from US Market | www.medscape.com

I read with great interest that Genentech, the maker of Raptiva (Efalizumab) to treat psoriasis, has begun a voluntary, phased withdrawal of the drug from the U.S. market. The drug is not being withdrawn immediately to give physicians and patients taking Raptiva time to safely and appropriately discontinue...

Various Generic Topiramate Tablets Approved by FDA

March 31, 2009

Kuldeepak Sharma, PhD, President/Pharmaceutical Consultant, Dr. Kuldeepak Sharma

Ranbaxy, Aurobindo get US FDA nod for epilepsy drug | economictimes.indiatimes.com

As a Pharmaceutical consultant and pharmacist I read this article with great interest since prices Topiramate will further reduced due to additional generic company. Topamax® is very useful drug for the treatment of adult and pediatric Epilepsy. On September 2006, Mylan Pharmaceuticals Inc. received...

No Bidding War For CV Therapeutics From Astellas

March 17, 2009

Kuldeepak Sharma, PhD, President/Pharmaceutical Consultant, Dr. Kuldeepak Sharma

Astellas to Terminate Offer for CV Therapeutics | www.pipelinereview.com

I read this news with great interest since I have worked with Astellas (Yamanouchi). Based on my experience with Astellas I am not surprise that Astellas did not increase prices (although Astellas had so much to gain from a merger with CV) due the these reasons: * Astellas (as a Japanese company) is...

View All GLG News SM Analyses by Kuldeepak Sharma, PhD

Leading institutions connect with Kuldeepak Sharma, PhD through GLG

GLG Study Groups with Kuldeepak Sharma, PhD(?)

Study Group Name No. Members
Physicians who Treat Onychomycosis (US) 121
Opana ER Prescribers (US) 105
Prescribers of Aldara (US) 84
Medical Tourism Experts 358

GLG Live Meetings with Kuldeepak Sharma, PhD(?)

Recent Seminars

July 31, 2007 | San Francisco

GLGi: Drug Delivery Technologies

View All GLG Live Meetings with Kuldeepak Sharma, PhD